ADC Therapeutics SA
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 |
|---|---|---|---|---|
| Revenue | $81.4M | $70.8M | $69.6M | $209.9M |
| Operating income | -$121.5M | -$130.7M | -$166.0M | -$123.3M |
| Cost of revenue | $5.8M | $5.9M | $2.5M | $3.3M |
| Cash from operations | -$141.2M | -$123.8M | -$118.7M | -$138.3M |
| Capital expenditure | $264,000 | $867,000 | $3.2M | $687,000 |
| Free cash flow | -$141.4M | -$124.7M | -$121.9M | -$139.0M |
| Impairments | $5.0M | — | — | — |
| Total assets | $323.1M | $322.0M | $354.8M | $490.9M |
| Total liabilities | $509.0M | $524.6M | $503.0M | $411.4M |
Shares outstanding 127.2M · Free float 68.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.